For what purpose has Nitric oxide been FDA approved?

Nitric oxide has been FDA approved specifically for the use in infants with hypoxic respiratory failure, particularly in cases related to conditions such as persistent pulmonary hypertension of the newborn (PPHN). In this context, nitric oxide acts as a potent vasodilator, which helps improve oxygenation by reducing pulmonary vascular resistance and increasing blood flow to the lungs. This therapeutic use is critical because infants with hypoxic respiratory failure require immediate intervention to ensure adequate oxygen delivery to vital organs.

The other options do not align with the specific FDA approval for nitric oxide. While nitric oxide has been studied in various respiratory conditions, its approval does not extend to the treatment of asthma in adults, management of chronic obstructive pulmonary disease, or alleviation of allergic reactions. Each of these conditions requires different treatment approaches and therapies that are not related to the approved use of nitric oxide in neonates. Understanding this distinction is crucial for healthcare professionals when considering treatment options for respiratory failure in infants.